Beranda › Kanker Paru › Kansas › Overland Park
Uji klinis Kanker Paru di Overland Park, KS
11 studi untuk Kanker Paru mencari peserta di lokasi sekitar Overland Park (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Menerima pesertaFase 3
- Saint Luke's South Hospital, Overland Park
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Menerima pesertaFase 1/2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauhnya
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- University of Kansas Cancer Center-Overland Park, Overland Park
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Menerima pesertaFase 3
- University of Kansas Cancer Center-Overland Park, Overland Park
Integrated Cancer Repository for Cancer Research
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Saint Luke's Cancer Instititute - South, Overland Park
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauhnya
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauhnya
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauhnya
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Menerima pesertaFase 1/2
- The University of Kansas Cancer Center, Fairway · 3 mi jauhnya
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Menerima pesertaStudi observasional
- Aton Health, Leawood · 3 mi jauhnya
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
Menerima pesertaStudi observasional
- The University of Kansas Cancer Center (KUCC), Fairway · 3 mi jauhnya
Uji klinis Kanker Paru di kota lain
- Houston, TX78 studi
- Boston, MA62 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Arlington, VA41 studi
- Washington, DC41 studi
- Chicago, IL41 studi
- Baltimore, MD40 studi
- Nashville, TN40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
Studi lain di Overland Park
- Kanker Paru Non-Sel Kecil16 studi
- Leukemia Mieloid Akut11 studi
- Kanker Payudara10 studi
- Fibrilasi Atrium8 studi
- Kanker Kolorektal8 studi
- Obesitas7 studi
- Kanker Pankreas7 studi
- Kanker Prostat7 studi
- Melanoma6 studi
- Kelebihan Berat Badan6 studi
- Kanker Ovarium6 studi
- Kanker (semua jenis)5 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.